



ASX ANNOUNCEMENT

Starpharma presents at ASX Emerging Growth Conference

Melbourne, Australia; Thursday 10th March 2011 – Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is today presenting at the ASX Emerging Growth conference in London.

More than 150 institutional fund managers are confirmed for the event. Starpharma is one of 18 companies participating in this invitation only event, and one of only two healthcare companies. Mesoblast is the other.

The London event is part of the ASX Spotlight Series in which Starpharma participated last year presenting to institutional investors in both Hong Kong (October 2010) and Singapore (May 2010).

The presentation by CEO Dr Jackie Fairley is attached, and covers:

- Starpharma's unique and valuable platform technology based on dendrimers – a nanotechnology that is being applied to pharmaceuticals, drug delivery and agricultural applications.
- Lead product VivaGel[®], a topical microbicide under development for the prevention of sexually transmitted infections including genital herpes, human papillomavirus and HIV. It is also under development as a condom coating licensed to Reckitt Benckiser.
- Progress of the phase 2 clinical program for the study of VivaGel[®] for both the treatment and prevention of recurrence of bacterial vaginosis (BV), the most common vaginal infection worldwide. The treatment market alone for BV is in excess of US\$300M currently with the prevention market likely to be substantially larger again.
- Other important applications of dendrimers including drug delivery and agrochemicals.
- Recent expansion of the agrochemical program following the receipt of a \$250,000 grant from the Victorian Government.
- A successful business model of partnering with market-leading companies to maximise the value of Starpharma's technology. Partners include Reckitt Benckiser, Lilly, Siemens Healthcare, GSK, Elanco, and EMD Merck.

The ASX conference involves emerging Australian companies with a market capitalisation of up to AU\$2B. Details of the London event are available at:

<http://www.asx.com.au/smalltomidcaps/london/>

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer technology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA.

The Company's lead pharmaceutical development product is VivaGel[®] (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. Starpharma has a licence agreement with Reckitt Benckiser (LSE:RB) to develop a VivaGel[®] coated condom. Reckitt Benckiser manufactures and sells Durex[®] condoms, the market-leading condom brand worldwide.

Starpharma also has agreements in place with Lilly, Elanco, Stiefel Laboratories (a GSK Company), and Unilever as well as many research collaborations with some of the world's leading organisations.

Dendrimer: A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

American Depositary Receipts (ADRs): Starpharma's ADRs trade under the code **SPHRY** (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Securities Exchange (ASX). The Bank of New York Mellon is the depositary bank. Starpharma's ADRs are listed on International OTCQX, a premium market tier in the U.S. for international exchange-listed companies, operated by OTC Markets Group Inc. (www.otcm Markets.com).

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

FOR FURTHER INFORMATION

Media:

Buchan Consulting
Rebecca Wilson
Mob: +61 417 382 391
rwilson@bcg.com.au

Starpharma:

Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704

Ben Rogers
Company Secretary
+61 3 8532 2702
ben.rogers@starpharma.com



Starpharma Holdings Limited

ASX:SPL
OTCQX:SPHRY

ASX Emerging Growth Conference

London, 10 March 2011

Dr. Jackie Fairley CEO



This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Certain VivaGel studies are funded by U.S. NIH/NIAID/DAIDS, Contract No. HHSN266200500042C. The content of this presentation does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.



Starpharma Holdings Limited - ASX:SPL

Investment Summary

Attractive commercial partnership for VivaGel® coated condom

- VivaGel® Condom Coating licensed to Reckitt Benckiser (RB)
- Sales/royalty revenues expected to commence in CY11
- Japanese rights under negotiation (the world's 2nd largest condom market)

Lead product VivaGel® in mid-stage clinical trials:

- Gel to protect women from HIV/HSV2/HPV (sexually transmitted infections) in Phase 2 clinical development
- Phase 2 trial program for VivaGel® in Bacterial Vaginosis
 - BV Treatment Trial nearing completion
 - BV Recurrence prevention planned 2H CY 11

Multiple partnerships already in place for Starpharma's dendrimers with an active BD program to expand:

- Drug delivery deals with companies including Lilly, Elanco, GSK/Stiefel
- Medical technology deals (Siemens, Aldrich, Merck, Qiagen)
- Agrochemical deals, including with multi-billion dollar US Ag. Company
- Other opportunities: Industrial, cosmetic, water treatment

8 March 2011

ASX Code	SPL
Share Price SPL AUD	\$1.10
52 Week Range AUD	46c-\$1.22
Shares on Issue	244M
Market Capitalisation AUD	~ \$270M
Average Mthly Volume: ASX	~ 10M shares
Average Mthly Volume: OTCQX (Code: SPHRY)	~ 1M shares
Cash (AUD) 31/12/10	\$19.7M
Major Shareholders	Acorn Orbis Dow



Dendrimers – A Versatile, Proprietary “Platform” Technology

Starpharma’s strategy - to generate a series of parallel revenue streams

“Dendrimers have numerous potential applications in healthcare and industry. We see the possibility of lucrative licensing deals from dendrimer projects focused on drug delivery, animal health, agro-chemicals and many more”


Southern Cross Equities, 1 Feb 2011

“The numerous commercial options make Starpharma one of the most exciting biotech companies listed on the ASX.”

Shaw Stockbroking, 3 March 2011

“Starpharma provides excellent exposure to the biotech sector, without the development and expenditure risks attributable to late stage therapeutic players.”

Taylor Collison, 23 Mar 2010



Starpharma’s dendrimers are highly branched polymers with versatile commercial applications

Starpharma holds more than 100 granted patents in the dendrimer space



Starpharma's Commercial Partnerships

Starpharma's aim is to partner with market-leading companies



VivaGel®

Co-development and licence for Condom Coating (excl. Japan)



Dendrimers for Drug Delivery

Lilly, Elanco, Stiefel (GSK); Drug delivery collaborations

*Multibillion dollar US
Agrochemical company*

Dendrimers for Agrochemicals



Stratus CS®

Various diagnostics licensed to Siemens Healthcare (Dade Behring)



SuperFect®

Gene transfection technology licensed to Qiagen



Starburst®

Dendrimers commercially available via Sigma Aldrich



Prioject® : siRNA & DNA transfection reagents



Pipeline: Dendrimers – A Versatile “Platform” Technology

	Early or lead	Development	Marketed
VivaGel® Condom Coating Gel : HIV/HSV preventative Gel : BV treatment	 		
drug delivery	 Undisclosed 		
diagnostics	 Undisclosed		
laboratory reagents	 		
agrochemical	Undisclosed		
Cosmetic/ industrial etc.			



VivaGel® - 2 Products: Anti-viral Condom Coating and Microbicide Gel

VivaGel®-Coated Condom



Condom coated with patented antiviral
- inactivates viral STIs
(HIV, Herpes, HPV)



Licensed to
Reckitt Benckiser

Combination Product
(Device Branch review)

Product

Commercialization Strategy

Regulatory path

VivaGel®



Topical Microbicide Gel
- for the prevention of
viral STIs (HIV, Herpes, HPV)

In-house development,
late stage license

Standard Pharmaceutical;
FDA Fast Track



VivaGel® Condom Coating License Agreement with Reckitt Benckiser


- **Starpharma to receive:**
 - royalties on Reckitt Benckiser sales (RB acquired SSL Nov 2010)
 - development assistance and milestones
- **Value to Starpharma:**
 - Near term revenue potential (device route)
 - Enhancement of VivaGel® brand
 - Commercial validation
- **Reckitt Benckiser to market globally (except Japan)**
 - Global household and healthcare product company **LSE:RB**
 - Major healthcare brands include **Clearasil®**, **Strepsils®**, **Nurofen®**, **Durex®** and **Scholl®**
 - **Durex®**
 - No. 1 global condom brand (~42% share)
 - Designated a Reckitt "Power-brand"
- **Japanese rights under negotiation (2nd largest condom market)**

Global Condom Market

Total Sales: US\$3.26B[^](2006)
 Top 4 sales: 70% of total
 Sales Growth: 4-5% annually

Chief Factor in growth:
awareness of AIDS and STIs

Global Market Share



source: "[^]Condoms - a global strategic business report 2006", Annual Reports and industry data.

Condoms represent a US\$3.26B market; Branded condoms ~\$1.1B




VivaGel®-Coated Condom



- Anti-viral Condom Coating
- Value-added product, focussed on a key driver of condom sales growth: STIs
- Licensed to Reckitt Benckiser (owner of Durex®)
- Combination Product

Starpharma Income Scenarios



Key Assumptions:

- Global **Branded** Condom Market est: US\$1.1 - \$1.7 B
- SSL/RB Global market Share 40 -42%
- Market Growth Rate pa. 5%
- Patent expiry 2027 (excl. extensions)

Potential upsides (not included):

- Further RB share growth, Market growth >5%



Commercial Opportunity for Microbicides

Genital Herpes an important health issue and key driver

Genital Herpes: a major health issue in the USA and Europe


- Affects >50 million Americans today ; 26% women in the USA and 15-20% adults in Europe
- 40-50% of women in the U.S. by 2025 (estimated)
- Recurrent, lifelong viral infection;
- Herpes infected individuals 6-8x increased risk of HIV
- Alternative prevention options are limited; vaccines ineffective
- VivaGel® is the only microbicide being developed for Herpes prevention

Industry surveys confirm strong consumer demand for microbicides

- 30 - 40% of female US college students would buy a microbicide effective against STIs
- Other studies: >20 million women in US would use a microbicide



Estimated Market* for Microbicides in Developed Countries only



Independent Microbicide market estimates: US\$1.5-6 Billion

Source: World Bank; UNAIDS; EC AIDS survey; BCG analysis, various analyst and microbicide publications;

*Key assumptions: 291m women of reproductive age (15-49) in developed countries Unit sale price ~ US\$2; Usage rates according to published data



VivaGel[®]: Human Papilloma Virus (HPV) Activity

VivaGel[®] has broad activity in HPV strains not currently addressed by existing vaccines


	HPV-5	HPV-6	HPV-11	HPV-16	HPV-18	HPV-31	HPV-45
Genital warts	Cutaneous infection	✓	✓				
Cervical Carcinoma				✓	✓	✓	✓
Gardasil[®] (CSL/Merck)	✗	✓	✓	✓	✓	✗	✗
Cervarix[®] GSK	✗	✗	✗	✓	✓	✗	✗
VivaGel[®] SPL7013*	✓	✓	✓	✓	✓	✓	✓

* In-vitro results obtained at NCI and University of Queensland



VivaGel® Clinical Development Status

Prevention of Genital Herpes and HIV (and potentially HPV)



- Currently in mid-stage clinical trials for HIV and Genital Herpes
- 5 Clinical Trials in >200 people
- Safe and well tolerated in humans
- Potent and longstanding antiviral activity in humans
- Non-dilutive NIH funding >US\$26m; extensive development package
- US FDA Fast Track Status

New applications identified - Bacterial Vaginosis (BV); Phase 2 trial program now underway

1. BV Treatment and
2. BV Prevention of Recurrence



VivaGel® - Bacterial Vaginosis (BV) –Treatment and Prevention of Recurrence

An Attractive Commercial Opportunity

- The most common vaginal infection worldwide
- 21 million women (~29% women aged 14-49) infected in US, (up to 51% in certain demographics)
- Causes unpleasant discharge, increased risk STIs, linked to preterm birth
- Global market for ***topical*** BV treatments alone: approx. US\$300-350M
- Shortcomings amongst current antibiotic treatments:
 - Low cure rates < 50% and high rate of recurrence
 - Adverse effects: toxicity, reaction with alcohol, incompatibility with condoms

- VivaGel® clinical safety trials showed BV resolution in a number of human participants
- Lab tests show desirable differential action between normal flora (*Lactobacilli spp.*) & pathogenic bacteria (*G. vaginalis, Bacteroides, Prevotella.*)
- Phase 2 Trial for VivaGel® BV treatment underway; prevention of recurrence to commence 2011



VivaGel® - Bacterial Vaginosis (BV) – An attractive Commercial Opportunity

Treatment and Prevention of Recurrence – 2 separate market opportunities

Indication	Current Market/est.	Existing therapies	Stage of Development	Commercial Strategy
BV Treatment	US \$300-350M (topical agents alone)	Metronidazole Clindamycin (antibiotics)	Phase 2 Trial underway; results Q2 2011	Late stage Licence
Prevention of BV recurrence	Likely to be significantly larger than treatment	None approved	Phase 2 Trial commencing 2H 2011	Late stage Licence


Benefits of SPL7013 vs. current therapies:

Locally acting, selective effect, not systemically absorbed, compatible with latex condoms, lack of toxicity (associated with antibiotics)



Dendrimers for Drug Delivery

Advantages include – reduced toxicity, less frequent dosing and new patents



Capabilities of Starpharma's Technology include:

- Product lifecycle management (extend patent life)
- Improved efficacy of drugs
- Extension of drug half-life
- Reduced toxicity
- Active or passive targeting (e.g. EPR*)
- Improved solubility of drugs
- Drug "rescue"

**enhanced permeability & retention effect*

Starpharma's Delivery Partnerships:


- Eli Lilly and Company – human pharmaceuticals
- Stiefel Labs. Inc (a GSK company) – Dermal
- Lilly's Animal Health Division , Elanco
- Various additional, early stage





Dendrimers for Drug Delivery - Proteins and Peptide Drugs

Longer half life – less frequent dosing



Approach

Conjugate protein or peptide to functionalised dendrimer

Benefit


Control half life of protein or peptide therapeutics
Improve dosing regimen
Reduce protein metabolism

Status

in vivo using insulin for proof of concept **achieved**

Co-development program with undisclosed partner

In vivo mouse model




Dendrimer insulin shows prolonged suppression of blood glucose *in vivo*





Dendrimers for Drug Delivery

Efficacy - with reduced toxicity

Cardiac toxicity of one of world's most widely used cancer drugs (doxorubicin) reduced markedly



Mouse Tissue Deposition




...whilst preserving or enhancing drug function




Drug Delivery applications have the potential to create significant value

Examples of companies which have created value through drug delivery

<p>VivaGel®</p> <p>Condom Coating</p> <p>Drug Delivery Platform</p> <p>Agrochemicals</p> <p>Diagnostics</p> <p>Specialty Chemicals</p>	Company	Valuation	Therapeutic Focus	Value driver
	<p>Abraxis Bioscience Nasdaq: ABII ^</p>	<p>US\$2.9Bi ^Acquired by Celgene June 2009</p>	<p>Oncology</p>	<p>Abraxane : global sales >USD 300M. (a nanoparticle, Water soluble formulation of paclitaxel)</p> <p>Wider application to other therapies</p>
	<p>Nektar Therapeutics Nasdaq: NKTR</p>	<p>US\$1.35Bi (Market Capitalisation)</p>	<p>Oncology CNS Autoimmune Anti-infective Other</p>	<p>Pipeline and portfolio of novel products based on polymer delivery platform</p> <p>Partnerships with top tier biopharmaceutical companies</p>



Paclitaxel (Taxol®) & water



Paclitaxel-Dendrimer
 Water solubility > 9000x greater



Dendrimers for Drug Delivery

Starpharma's Dendrimers improve water solubility of the drug Taxol® by >9,000X

Paclitaxel (Taxol®)
6 mgs in 2 mL of water:
very poorly soluble



Dendrimer-Paclitaxel
construct :
highly soluble



**Potential Value of
Drug Delivery
technologies:**

**Celgene's acquisition of
Abraxis BioSciences Inc.
for \$2.9 Billion
(June 2010)**

Paclitaxel aqueous solubility 0.8 µg/mL*

* *Bull Korean Chem Soc.* 1999, Vol. 20, No 12, 1389 – 1390.

SPL Dendrimer version
aqueous solubility >37mg/mL
20% w/w Paclitaxel loading



Dendrimers in Agrochemicals



Starpharma signs agrochemicals deal

Melbourne, Australia; 5 November 2009 - Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the signing of a research and collaboration agreement between its wholly owned US subsidiary, DNT Inc, and a prominent, US-based agricultural chemicals company. The confidentiality provisions of the agreement prevent disclosure of the name of the collaborating company at this time.

Under the agreement the parties will use DNT's Priostar® dendrimer technology to enhance the performance of existing pesticides. The approach is a natural extension of Starpharma's drug delivery work, in which dendrimers extend the persistence of an active molecule, potentially reducing the amount of active that is required for a given effect.

The agreement applies to specific classes of pesticides, and does not prevent Starpharma's further commercialisation of dendrimers more widely in the agricultural chemicals sector.

- Extension of drug delivery technology
- Valuable new opportunity for dendrimers
- Agrochemicals market US\$124B (Pesticides US\$35.8B)
- Faster development than pharmaceuticals
- One agreement announced Nov. 2009 – a number of discussions in progress



Model demonstrating multiple points of attachment

Dendrimer can enhance the performance of existing agrochemicals

- Adhesion to difficult surfaces
- Extension of effect/
Controlled release
- Solublising
- Protection of Actives
- Sequestration



Starpharma expands its Agrochemical Program

Program involves applying SPL's dendrimer technology to various generic agrochemical agents

Top 10 Generic Agrochemicals[#]

Active Ingredient	Activity	Market Value (\$M USD)
Glyphosate	Herbicide	5000
Imidacloprid	Insecticide	1000
Malathion	Insecticide	400
Paraquat	Herbicide	400
Acephate	Insecticide	350
Pendimethalin	Herbicide	350
2,4-D	Herbicide	325
Acetochlor	Herbicide	300
Chlorpyrifos	Insecticide	300
Trifluralin	Herbicide	300

ASX ANNOUNCEMENT

Starpharma to expand agricultural program through \$250,000 funding

Melbourne Australia; Thursday 3rd March 2011– Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHY) has been awarded \$250,000 funding to enhance agrochemicals using its Priostar[®] dendrimers.

The funding, announced last night by the Minister of Technology, Gordon Rich-Phillips, as part of the Victorian Government's Small Technologies Industry Uptake Program (STIUP), will allow Starpharma to expand its Melbourne-based agricultural programs, further enhancing the commercial prospects of promising candidates.

Starpharma will be applying its Priostar[®] dendrimer technology to improve delivery of agrochemicals to enable healthier plant growth and fight plant disease. As well as increasing efficacy, improved delivery control of chemicals can reduce both the frequency of application and amount applied. Such innovations have the potential to reduce farmers' costs and also reduce environmental impact.



Starpharma's potential commercial returns

Starpharma aims to generate a series of parallel revenue streams

Product/Application	Indication/ Product	Commercial Strategy/ Partnering Status	Market Potential USD /Revenue model
VivaGel® Standalone Gel	STI (HIV/HSV2/HPV) Prevention Phase 2	License at late stage	\$3-6Bi ¹ USD
VivaGel® Standalone Gel	1. BV treatment 2. Prevention of recurrence Phase 2	License at late stage	1. BV Treatment: US\$300-350M ¹ 2. Recurrence market likely to be significantly greater due to repeat use
VivaGel® Coated Condom	Antiviral coating	Partnered with RB	\$1.1 - \$1.7 Bi ¹
Drug Delivery	Multiple	Multiple Partnered Programs include Lilly, GSK, Elanco, undisclosed	Undisclosed/Partner Funded research/downstream returns
Agrochemicals and Industrial	Multiple	Multiple Partnered Programs	Undisclosed/Partner Funded research/downstream returns



FY 2010 Financials and Value Drivers for Starpharma

	FY 2010 AUD \$M
Royalty, customer & license revenue	1.4
Grant, interest and other income	4.5
Total revenue and income	5.9
Net loss after tax	(6.4)
Net cash outflow before new capital (Cash Burn)	(3.9)
Cash at Bank (30/6/10)	22.8*
* Cash (31/12/10)	19.7

Value Drivers

VivaGel® - Coated Condom to market globally

Complete co-development with Reckitt and support product launch/roll-out

Sign marketing partner for Japan (the world's second largest condom market) and support commercial launch

Advance VivaGel® clinical development and commercialisation

Complete Phase 2 Bacterial Vaginosis program for treatment and suppression of recurrence; commence Phase-3

Advance Herpes/HPV/(HIV) efficacy trials and continue to explore public funding options;

Expand dendrimer-based commercial relationships

Advance existing & form new commercial partnerships – drug delivery, agrochemicals diagnostics etc.